101 related articles for article (PubMed ID: 1985738)
21. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?
Greipp PR; Trendle MC; Leong T; Oken MM; Kay NE; Van Ness B; Kyle RA
Leuk Lymphoma; 1999 Sep; 35(1-2):83-9. PubMed ID: 10512165
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.
Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G
Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometric DNA analysis and clinical correlations in multiple myeloma.
Tienhaara A; Pelliniemi TT
Am J Clin Pathol; 1992 Mar; 97(3):322-30. PubMed ID: 1543155
[TBL] [Abstract][Full Text] [Related]
24. [VAD chemotherapy of multiple myeloma].
Amano M; Itoh K; Togawa A
Rinsho Ketsueki; 1990 Jul; 31(7):917-21. PubMed ID: 2214189
[TBL] [Abstract][Full Text] [Related]
25. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
26. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
[TBL] [Abstract][Full Text] [Related]
27. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
[TBL] [Abstract][Full Text] [Related]
28. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Delain M; Linassier C; Petitdidier C; Goupille P; Luthier F; Combe M; Reisenleiter M; Benboubker L; Lamagnère JP; Colombat P
J Clin Oncol; 1994 Dec; 12(12):2706-13. PubMed ID: 7989948
[TBL] [Abstract][Full Text] [Related]
29. VAD chemotherapy as remission induction for multiple myeloma.
Anderson H; Scarffe JH; Ranson M; Young R; Wieringa GS; Morgenstern GR; Fitzsimmons L; Ryder D
Br J Cancer; 1995 Feb; 71(2):326-30. PubMed ID: 7841049
[TBL] [Abstract][Full Text] [Related]
30. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
Maniatis A; Stamatellou M; Papanastasiou K
Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
[No Abstract] [Full Text] [Related]
32. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications.
Bunn PA; Krasnow S; Makuch RW; Schlam ML; Schechter GP
Blood; 1982 Mar; 59(3):528-35. PubMed ID: 6800416
[TBL] [Abstract][Full Text] [Related]
33. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Barlogie B; Smith L; Alexanian R
N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
[TBL] [Abstract][Full Text] [Related]
34. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
[TBL] [Abstract][Full Text] [Related]
35. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.
Friedlander ML; Hedley DW; Swanson C; Russell P
J Clin Oncol; 1988 Feb; 6(2):282-90. PubMed ID: 3276825
[TBL] [Abstract][Full Text] [Related]
36. DNA cell content studies in multiple myeloma.
San Miguel JF; García-Sanz R; González M; Orfão A
Leuk Lymphoma; 1996 Sep; 23(1-2):33-41. PubMed ID: 9021683
[TBL] [Abstract][Full Text] [Related]
37. DNA-RNA measurements in patients with acute leukemia undergoing remission induction therapy.
Maddox AM; Johnston DA; Barlogie B; Youness E; Keating M; Freireich EJ
J Clin Oncol; 1985 Jun; 3(6):799-808. PubMed ID: 4009216
[TBL] [Abstract][Full Text] [Related]
38. [Comparative evaluation of treatment results in advanced multiple myeloma with the help of polychemotherapy with vincristine, doxorubicin, dexamethasone (VAD) or only with dexamethasone].
Hansz J; Włodarczyk M; Psuja P
Acta Haematol Pol; 1992; 23(4):277-84. PubMed ID: 1293910
[TBL] [Abstract][Full Text] [Related]
39. VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
Weber D; Dimopoulos M; Sinicrope F; Alexanian R
Leuk Lymphoma; 1995 Sep; 19(1-2):159-63. PubMed ID: 8574163
[TBL] [Abstract][Full Text] [Related]
40. Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma.
Wooldridge TN; Grierson HL; Weisenburger DD; Armitage JO; Sanger WG; Collins MM; Pierson JL; Pauza ME; Fordyce R; Purtilo DT
Cancer Res; 1988 Nov; 48(22):6608-13. PubMed ID: 3052808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
